Beyond the TRIBUTE trial: Integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC

Future Oncology

Volumn 2, Issue 1, 2006, Pages 47-51

  Reck, Martin ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Chemotherapy; Erlotinib; Lung cancer; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL TRIAL; DIARRHEA; DRUG ERUPTION; DRUG POTENTIATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PATIENT SELECTION; PHARMACOGENETICS; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PACLITAXEL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; SURVIVAL; TREATMENT OUTCOME; UP-REGULATION;

EID: 33646784386     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.1.47     Document Type: Article

References (27)

1. Herbst RS, Prager D, Hermann R et al.: TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
2. Haura EB: Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 8(4), 326-336 (2001).
3. Novello, S, Le Chevalier T: Chemotherapy for non-small-cell lung cancer. Part 2: advanced disease. Oncology 17(4), 457-464 (2003).
4. Ciardiello F, Tortora G: Anti-epidermal growth factor receptor drugs in cancer therapy. Exp. Opin. Invest Drugs 11, 755-768 (2002).
5. Arteaga C: Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin. Oncol. 30(3 Suppl. 7), 3-14 (2003).
6. Salomon DS, Brandt R, Ciardiello F, Normano N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183-232 (1995).
7. Shepherd F, Pereira J, Ciuleanu T et al.: Erlotinib in previously treated patients non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
8. Perez-Soler R, Chachoua A, Hammond LA et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22, 3238-3247(2004).
9. Higgins B, Kolinsky K, Smith M et al.: Antitumor activity of erlotinib (OSI-774, Tarceva™) alone or in combination in human non-small-cell lung cancer tumor xenograft models. AntiCancer Drugs 15, 503-512 (2004).
10. Akita RW, Sliwkowski MX: Preclinical studies with erlotinib (Tarceva™). Semin. Oncol. 30(Suppl. 7), 15-24 (2003).
11. Gatzemeier U. Pluzanska A, Szxzesna A et al.: Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 22(Suppl. 14), 617 (2004) (Abstract 7010).
12. Gatzemeier U, Heller A, Foernzler D et al.: Exploratory analyses of EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients treated with chemotherapy +/- erlotinib (TALENT). J. Clin. Oncol. 23(Suppl. 16S pt I), 627s (2005) (Abstract 7028).
13. Herbst RS, Giaccone G, Schiller JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 2. J. Clin. Oncol. 22, 785-794 (2004).
14. Giaccone G, Herbst RS, Manegold C, et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 1. J. Clin. Oncol. 22, 777-784 (2004).
15. Paez JG, Jänne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004).
16. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-239 (2004).
17. Pao W, Miller V, Zakowski M et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101(36), 13306-13311 (2004).
18. Eberhard DA, Johnson B, Amler LC et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23(25), 5900-5909 (2005).
19. Tsao MS, Sakurada A, Cutz JC et al.: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144 (2005).
20. Moyer JD, Barbacci EG, Iwata KK et al.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57, 4838-4848 (1997).
21. Hamilton M, Wolf J, Zborowski D et al.: Tarceva™ (erlotinib) exposure/ effects (EE) analysis from a Phase III study in advanced NSCLC: Effect of smoking on the PK of erlotinib. Proc. Am. Assoc. Cancer Res. 46 (2005) (Abstract 6165).
22. Schiller JH, Harrington D, Belani CP et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92-98 (2002).
23. Kimura T et al.: Apoptotic effects of the docetaxel→OSI-774 combination in non-small cell lung carcinoma (NSCLC cells. J. Clin. Oncol. 22(Suppl. 14), 649 (2004) (Abstract 7143).
24. Davies AM, Lara PN, Lau DH et al.: Intermittent erlotinib in combination with docetaxel (DOC): Phase I schedules designed to achieve pharmacodynamic separation. J. Clin. Oncol. 23(Suppl. 16S pt I), 630s (2005) (Abstract 7038).
25. Giaccone G, Le Chevalier T, Thatcher N et al.: A Phase II study of erlotinib as firstline treatment of advanced non-small cell lung cancer. J. Clin. Oncol. 23(Suppl. 16S pt I), 683s (2005) (Abstract 7073).
26. Jackman DM, Lucca J, Fidias P et al.: A Phase II study of the, EGFR tyrosine kinase inhibitor erlotinib in patients >70 years of age with previously untreated advanced non-small-cell lung carcinoma. Eur. J. Cancer Supplements 3(2), 325 (2005) (Abstract 1127).
27. Herbst RS, Johnson DH, Mininberg E et al.: Phase I/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23(11), 2544-2555 (2005).